Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 72 of 1,261
  1. US 12187804

    Multivalent and multispecific 41BB-binding proteins

    Inhibrx Biosciences, Inc. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  2. US 12187779

    Anti-human papillomavirus 16 E6 T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  3. US 12187698

    Crystalline forms of C21H22Cl2N4O2

    Vertex Pharmaceuticals Incorporated · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  4. US 12187992

    Method and device for early cancer screening

    The Regents of the University of California · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  5. US 2025002606

    Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA

    BAVARIAN NORDIC AS [DK] · Granted Jan 2, 2025 · Expires Dec 28, 2044

    granted
  6. US 12180251

    Nucleic acids encoding peptides that block binding of a2d-1 to glutamate receptors for treating diseases and disorders

    The Board of Regents of the University of Texas System · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  7. US 12180300

    Targeting moiety-drug grafted immune cell compositions and methods of use

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  8. US 12181555

    3-dimensional representations of post-contrast enhanced brain lesions

    The Board of Regents of the University of Texas System · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  9. US 12181485

    Methods of blood screening

    CASI Pharmaceuticals, Inc · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  10. US 12180504

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  11. US 12180503

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  12. US 12180479

    Compounds and methods for modulating ATXN1

    Ionis Pharmaceuticals, Inc. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  13. US 12180192

    Modulators of THR-β and methods of use thereof

    Aligos Therapeutics, Inc. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  14. US 12180225

    N/O-linked degrons and degronimers for protein degradation

    C4 THERAPEUTICS, INC. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  15. US 12180509

    Methods for reprograming non-pluripotent cells into pluripotent stem cells

    BeiHao Stem Cell and Regenerative Medicine Research Institute Co., Ltd. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  16. US 12180484

    Chimeric antigen receptors targeting B-cell maturation antigen

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  17. US 12180471

    Antisense oligonucleotides for the treatment of Stargardt disease

    ProQR Therapeutics II B.V. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  18. US 12180277

    LILRB4-binding antibody and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  19. US 12178921

    Method of lyophilizing lipid nanoparticles

    ARCTURUS THERAPEUTICS, INC. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  20. US 12178875

    Lymphatic system-directing lipid prodrugs

    Seaport Therapeutics, Inc. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  21. US 12180463

    Lactobacillus reuteri

    PrecisionBiotics Group Limited · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  22. US 12180272

    Antigen binding molecule formats

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  23. US 12180258

    T-cell modulatory multimeric polypeptides and methods of use thereof

    Cue Biopharma, Inc. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  24. US 12180211

    Compounds, compositions and methods

    DENALI THERAPEUTICS INC. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.